Bryostatin 1, A New Anti-tumor Agent: From Bench to Bedside
Keywords: Bryostatin 1, B-cell tumors, Differentiation, Apoptosis, bc12, c-myc, p53
AbstractBryostatin 1 represents a novel natural agent that appears to exert pleiotropic biological effects via protein kinase C (PKC). Bryostatin 1 has been found to have anti-neoplastic and immunomodulatory activity in a variety of in vitor and in vivo systems. Although Bryostatin 1 exhibits its dose dependent inhibitory response on solid tumor lines as well, it has more potential against human leukemias and lymphomas. Extensive studies over the past several years have recently led Bryostatin 1 to enter phase 1 clinical trials for patients wilh lymphoma and leukemia tumors in our institute.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).